The biology of Hodgkin's lymphoma

Nature Reviews Cancer

Volumn 9, Issue 1, 2009, Pages 15-27

  Küppers, Ralf ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; STAT3 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; STAT6 PROTEIN;

B LYMPHOCYTE; CELL INFILTRATION; CELL MATURATION; EPSTEIN BARR VIRUS; HODGKIN DISEASE; HUMAN; MICROENVIRONMENT; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REED STERNBERG CELL; REVIEW; SIGNAL TRANSDUCTION; VIRUS INFECTION;

B-LYMPHOCYTES; CELL DEDIFFERENTIATION; CELL TRANSFORMATION, VIRAL; EPSTEIN-BARR VIRUS INFECTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; GERMINAL CENTER; HERPESVIRUS 4, HUMAN; HODGKIN DISEASE; HUMANS; INFLAMMATION; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASM PROTEINS; REED-STERNBERG CELLS; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; TUMOR ESCAPE; VIRAL PROTEINS;

EID: 57749171165     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2542     Document Type: Review

References (164)

1. Hodgkin, T. On some morbid appearances of the absorbent glands and spleen. Med. Chir. Trans. 17, 68-114 (1832).
2. Reed, D. On the pathological changes in Hodgkin's disease with special reference to its relation to tuberculosis. John Hopkins Hosp. Rep. 10, 133-193 (1902).
3. Sternberg, C. Übe r eine eigenartige unter dem Bilde der Pseudoleukämie verlaufende Tuberkolose des lymphatischen Apparates. Z. Heilkunde 19, 21-90 (1898) (in German).
4. Jaffe, E. S., Harris, N. L., Stein, H. & Vardiman, J. W. WHO Classification of Tumors: Pathology and Genetics of Tumors of Haematopoietic and Lymphoid Tissues (IARC Press, Lyon, 2001).
5. Diehl, V., Thomas, R. K. & Re, D. Part II: Hodgkin's lymphoma - diagnosis and treatment. Lancet Oncol. 5, 19-26 (2004).
6. Rajewsky, K. Clonal selection and learning in the antibody system. Nature 381, 751-758 (1996).
7. Küppers, R., Zhao, M., Hansmann, M. L. & Rajewsky, K. Tracing B cell development in human germinal centres by molecular analysis of single cells picked from histological sections. EMBO J. 12, 4955-4967 (1993).
8. Allen, C. D., Okada, T. & Cyster, J. G. Germinal-center organization and cellular dynamics. Immunity 27, 190-202 (2007).
9. Carbone, A. et al. Expression status of BCL-6 and syndecan-1 identifies distinct histogenetic subtypes of Hodgkin's disease. Blood 92, 2220-2228 (1998).
10. Greiner, A. et al. Differential expression of activation-induced cytidine deaminase (AID) in nodular lymphocyte-predominant and classical Hodgkin lymphoma. J. Pathol. 205, 541-547 (2005).
11. Hansmann, M.-L., Weiss, L. M., Stein, H., Harris, N. L. & Jaffe, E. S. in Hodgkin's Disease (eds Mauch, P. M., Armitage, J. O., Diehl, V., Hoppe, R. T. & Weiss, L. M.) 169-180 (Lippencott Williams & Wilkins, Philadelphia, 1999).
12. Braeuninger, A. et al. Hodgkin and Reed-Sternberg cells in lymphocyte predominant Hodgkin disease represent clonal populations of germinal center-derived tumor B cells. Proc. Natl Acad. Sci. USA 94, 9337-9342 (1997).
13. Küppers, R. et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc. Natl Acad. Sci. USA 91, 10962-10966 (1994). The first demonstration that HRS and L&H cells are clonal populations of B cells.
14. Marafioti, T. et al. Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. N. Engl. J. Med. 337, 453-458 (1997).
15. Brune, V. et al. Origin and pathogenesis of nodular lymphocyte-predominant Hodgkin lymphoma as revealed by global gene expression analysis. J. Exp. Med. 205, 2251-2268 (2008).
16. Kanzler, H., Küppers, R., Hansmann, M. L. & Rajewsky, K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J. Exp. Med. 184, 1495-1505 (1996). This study provided the first evidence that HRS cells are derived from 'crippled', BCR-deficient germinal centre B cells.
17. Bräuninger, A., Wacker, H. H., Rajewsky, K., Küppers, R. & Hansmann, M. L. Typing the histogenetic origin of the tumor cells of lymphocyte-rich classical Hodgkin's lymphoma in relation to tumor cells of classical and lymphocyte-predominance Hodgkin's lymphoma. Cancer Res. 63, 1644-1651 (2003).
18. Küppers, R. & Rajewsky, K. The origin of Hodgkin and Reed/Sternberg cells in Hodgkin's disease. Annu. Rev. Immunol. 16, 471-493 (1998).
19. Klein, U. et al. Somatic hypermutation in normal and transformed human B cells. Immunol. Rev. 162, 261-280 (1998).
20. Irsch, J. et al. Class switch recombination was specifically targeted to immunoglobulin (Ig)G4 or IgA in Hodgkin's disease-derived cell lines. Br. J. Haematol. 113, 785-793 (2001).
21. Martin-Subero, J. I. et al. Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Cancer Res. 66, 10332-10338 (2006).
22. Bräuninger, A. et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and Non-Hodgkin's lymphoma. N. Engl. J. Med. 340, 1239-1247 (1999).
23. Marafioti, T. et al. Classical Hodgkin's disease and follicular lymphoma originating from the same germinal center B cell. J. Clin. Oncol. 17, 3804-3809 (1999). References 22 and 23 demonstrated the close relationship of classical Hodgkin's lymphoma and non-Hodgkin's lymphomas by identifying common germinal centre B-cell precursors in composite lymphomas.
24. Müschen, M. et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J. Exp. Med. 191, 387-394 (2000).
25. Seitz, V. et al. Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood 95, 3020-3024 (2000).
26. Tzankov, A. et al. Rare expression of T-cell markers in classical Hodgkin's lymphoma. Mod. Pathol. 18, 1542-1549 (2005).
27. Aguilera, N. S. et al. Gene rearrangement and comparative genomic hybridization studies of classic Hodgkin lymphoma expressing T-cell antigens. Arch. Pathol. Lab. Med. 130, 1772-1779 (2006).
28. Willenbrock, K. et al. T-cell variant of classical Hodgkin's lymphoma with nodal and cutaneous manifestations demonstrated by single-cell polymerase chain reaction. Lab. Invest. 82, 1103-1109 (2002).
29. Barry, T. S., Jaffe, E. S., Sorbara, L., Raffeld, M. & Pittaluga, S. Peripheral T-cell lymphomas expressing CD30 and CD15. Am. J. Surg. Pathol. 27, 1513-1522 (2003).
30. Willenbrock, K. et al. Common features and differences in the transcriptome of large cell anaplastic lymphoma and classical Hodgkin's lymphoma. Haematologica 91, 596-604 (2006).
31. Küppers, R. Mechanisms of B-cell lymphoma pathogenesis. Nature Rev. Cancer 5, 251-262 (2005).
32. Schwering, I. et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 101, 1505-1512 (2003). This study demonstrated the global downregulation of B-cell molecules in HRS cells.
33. Carbone, A. et al. Expression of functional CD40 antigen on Reed-Sternberg cells and Hodgkin's disease cell lines. Blood 85, 780-789 (1995).
34. Van Gool, S. W. et al. Expression of B7-2 (CD86) molecules by Reed-Sternberg cells of Hodgkin's disease. Leukemia 11, 846-851 (1997).
35. Mathas, S. et al. Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma. Nature Immunol. 7, 207-215 (2006). This paper provided insight into the mechanisms involved in the reprogramming of HRS cells.
36. Takahashi, H. et al. Immunophenotypes of Reed-Sternberg cells and their variants: a study of 68 cases of Hodgkin's disease. Tohoku J. Exp. Med. 177, 193-211 (1995).
37. Drexler, H. G. Recent results on the biology of Hodgkin and Reed-Sternberg cells. I. Biopsy material. Leuk. Lymphoma 8, 283-313 (1992).
38. van den Berg, A., Visser, L. & Poppema, S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltration Hodgkin's lymphoma. Am. J. Pathol. 154, 1685-1691 (1999).
39. Re, D. et al. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res. 61, 2080-2084 (2001).
40. Stein, H. et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 97, 496-501 (2001).
41. Torlakovic, E., Tierens, A., Dang, H. D. & Delabie, J. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am. J. Pathol. 159, 1807-1814 (2001).
42. Doerr, J. R. et al. Patterned CpG methylation of silenced B cell gene promoters in classical Hodgkin lymphoma-derived and primary effusion lymphoma cell lines. J. Mol. Biol. 350, 631-640 (2005).
43. Ushmorov, A. et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 107, 2493-2500 (2005).
44. Hertel, C. B., Zhou, X. G., Hamilton-Dutoit, S. J. & Junker, S. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene 21, 4908-4920 (2002).
45. Pongubala, J. M. et al. Transcription factor EBF restricts alternative lineage options and promotes B cell fate commitment independently of Pax5. Nature Immunol. 9, 203-215 (2008).
46. Küppers, R. et al. Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling. J. Clin. Invest. 111, 529-537 (2003).
47. Renné, C. et al. Aberrant expression of ID2, a suppressor of B-cell-specific gene expression, in Hodgkin's lymphoma. Am. J. Pathol. 169, 655-664 (2006).
48. Hacker, C. et al. Transcriptional profiling identifies Id2 function in dendritic cell development. Nature Immunol. 4, 380-386 (2003).
49. Yokota, Y. et al. Development of peripheral lymphoid organs and natural killer cells depends on the helix-loop-helix inhibitor Id2. Nature 397, 702-706 (1999).
50. Foss, H. D. et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 94, 3108-3113 (1999).
51. Cobaleda, C., Schebesta, A., Delogu, A. & Busslinger, M. Pax5: the guardian of B cell identity and function. Nature Immunol. 8, 463-470 (2007).
52. Jundt, F. et al. Activated Notch 1 signaling promotes tumor cell proliferation and survival in Hodgkin and anaplastic large cell lymphoma. Blood 99, 3398-3403 (2001).
53. Jundt, F. et al. Aberrant expression of Notch1 interferes with the B-lymphoid phenotype of neoplastic B cells in classical Hodgkin lymphoma. Leukemia 22 1587-1594 (2008). References 52 and 53 showed aberrant expression of notch 1 in HRS cells and that this contributes to the lost B-cell phenotype of these cells.
54. Scheeren, F. A. et al. IL-21 is expressed in Hodgkin lymphoma and activates STAT5; evidence that activated STAT5 is required for Hodgkin lymphomagenesis. Blood 111, 4706-4715 (2008).
55. Schneider, E. M. et al. The early transcription factor GATA-2 is expressed in classical Hodgkin's lymphoma. J. Pathol. 204, 538-545 (2004).
56. Kumano, K. et al. Notch1 inhibits differentiation of hematopoietic cells by sustaining GATA-2 expression. Blood 98, 3283-3289 (2001).
57. Dukers, D. F. et al. Unique polycomb gene expression pattern in Hodgkin's lymphoma and Hodgkin's lymphoma-derived cell lines. Am. J. Pathol. 164, 873-881 (2004).
58. Raaphorst, F. M. et al. Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am. J. Pathol. 157, 709-715 (2000).
59. Sanchez-Beato, M. et al. Abnormal PcG protein expression in Hodgkin's lymphoma. Relation with E2F6 and NFkappaB transcription factors. J. Pathol. 204, 528-537 (2004).
60. Hu, M. et al. Multilineage gene expression precedes commitment in the hemopoietic system. Genes Dev. 11, 774-785 (1997).
61. Miyamoto, T. et al. Myeloid or lymphoid promiscuity as a critical step in hematopoietic lineage commitment. Dev. Cell 3, 137-147 (2002).
62. Dutton, A. et al. Bmi-1 is induced by the Epstein-Barr virus oncogene LMP1 and regulates the expression of viral target genes in Hodgkin lymphoma cells. Blood 109, 2597-2603 (2007).
63. Feuerborn, A. et al. Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma. Leuk. Lymphoma 47, 1932-1940 (2006).
64. Maggio, E. M., Stekelenburg, E., Van den Berg, A. & Poppema, S. TP53 gene mutations in Hodgkin lymphoma are infrequent and not associated with absence of Epstein-Barr virus. Int. J. Cancer 94, 60-66 (2001).
65. Montesinos-Rongen, M., Roers, A., Küppers, R., Rajewsky, K. & Hansmann, M.-L. Mutation of the p53 gene is not a typical feature of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood 94, 1755-1760 (1999).
66. Kashkar, H. et al. XIAP-mediated caspase inhibition in Hodgkin's lymphoma-derived B cells. J. Exp. Med. 198, 341-347 (2003).
67. Dutton, A. et al. Expression of the cellular FLICE-inhibitory protein (c-FLIP) protects Hodgkin's lymphoma cells from autonomous Fas-mediated death. Proc. Natl Acad. Sci. USA 101, 6611-6616 (2004).
68. Mathas, S. et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J. Exp. Med. 199, 1041-1052 (2004).
69. Wlodarska, I. et al. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood 101, 706-710 (2003).
70. + Hodgkin cells. Cancer Res. 60, 549-552 (2000).
71. Weniger, M. A. et al. Mutations of the tumor suppressor gene SOCS-1 in classical Hodgkin lymphoma are frequent and associated with nuclear phospho-STAT5 accumulation. Oncogene 25, 2679-2684 (2006). This paper showed that frequent somatic mutations in SOCS1 in HRS cells were probably a factor contributing to constitutive STAT activity in these tumour cells.
72. Mottok, A., Renné, C., Willenbrock, K., Hansmann, M. L. & Bräuninger, A. Somatic hypermutation of SOCS1 in lymphocyte-predominant Hodgkin lymphoma is accompanied by high JAK2 expression and activation of STAT6. Blood 110, 3387-3390 (2007).
73. Barth, T. F. et al. Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma. Blood 101, 3681-3686 (2003).
74. Joos, S. et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood 99, 1381-1387 (2002).
75. Martin-Subero, J. I. et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 99, 1474-1477 (2002).
76. Martin-Subero, J. I. et al. Chromosomal rearrangements involving the BCL3 locus are recurrent in classical Hodgkin and peripheral T-cell lymphoma. Blood 108, 401-402 (2006).
77. Mathas, S. et al. Elevated NF-κB p50 complex formation and Bcl-3 expression in classical Hodgkin, anaplastic large-cell, and other peripheral T-cell lymphomas. Blood 106, 4287-4293 (2005).
78. Cabannes, E., Khan, G., Aillet, F., Jarrett, R. F. & Hay, R. T. Mutations in the IκBα gene in Hodgkin's disease suggest a tumour suppressor role for IκBα. Oncogene 18, 3063-3070 (1999).
79. Emmerich, F. et al. Overexpression of I kappa B alpha without inhibition of NF-κB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 94, 3129-3134 (1999).
80. Jungnickel, B. et al. Clonal deleterious mutations in the IκBα gene in the malignant cells in Hodgkin's disease. J. Exp. Med. 191, 395-401 (2000). References 78-80 established somatic mutations in NFKBIA in a fraction of Hodgkin's lymphoma cases as a cause for constitutive NF-κB activity in HRS cells.
81. Emmerich, F. et al. Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J. Pathol. 201, 413-420 (2003).
82. Baus, D. & Pfitzner, E. Specific function of STAT3, SOCS1, and SOCS3 in the regulation of proliferation and survival of classical Hodgkin lymphoma cells. Int. J. Cancer 118, 1404-1413 (2006).
83. Kube, D. et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood 98, 762-770 (2001).
84. Skinnider, B. F. et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 99, 618-626 (2002).
85. Kapp, U. et al. Interleukin 13 is secreted by and stimulates the growth of Hodgkin and Reed-Sternberg cells. J. Exp. Med. 189, 1939-1946 (1999).
86. Hinz, M. et al. Nuclear factor κB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J. Exp. Med. 196, 605-617 (2002).
87. Lamprecht, B. et al. Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3α. Blood 112, 3339-3347 (2008).
88. Chiu, A. et al. Hodgkin lymphoma cells express TACI and BCMA receptors and generate survival and proliferation signals in response to BAFF and APRIL. Blood 109, 729-739 (2007).
89. Fiumara, P. et al. Functional expression of receptor activator of nuclear factor κB in Hodgkin disease cell lines. Blood 98, 2784-2790 (2001).
90. Schwab, U. et al. Production of a monoclonal antibody specific for Hodgkin and Sternberg-Reed cells of Hodgkin's disease and a subset of normal lymphoid cells. Nature 299, 65-67 (1982).
91. Carbone, A., Gloghini, A., Gruss, H. J. & Pinto, A. CD40 ligand is constitutively expressed in a subset of T cell lymphomas and on the microenvironmental reactive T cells of follicular lymphomas and Hodgkin's disease. Am. J. Pathol. 147, 912-922 (1995).
92. Molin, D. et al. Mast cells express functional CD30 ligand and are the predominant CD30L-positive cells in Hodgkin's disease. Br. J. Haematol. 114, 616-623 (2001).
93. Pinto, A. et al. Human eosinophils express functional CD30 ligand and stimulate proliferation of a Hodgkin's disease cell line. Blood 88, 3299-3305 (1996).
94. Hirsch, B. et al. CD30-induced signaling is absent in Hodgkin's cells but present in anaplastic large cell lymphoma cells. Am. J. Pathol. 172, 510-520 (2008).
95. Horie, R. et al. Ligand-independent signaling by overexpressed CD30 drives NF-κB activation in Hodgkin-Reed-Sternberg cells. Oncogene 21, 2493-2503 (2002).
96. Nishikori, M., Ohno, H., Haga, H. & Uchiyama, T. Stimulation of CD30 in anaplastic large cell lymphoma leads to production of nuclear factor-κB p52, which is associated with hyperphosphorylated Bcl-3. Cancer Sci. 96, 487-497 (2005).
97. Schwaller, J. et al. Paracrine promotion of tumor development by the TNF ligand APRIL in Hodgkin's disease. Leukemia 21, 1324-1327 (2007).
98. Cheng, P. et al. Notch-1 regulates NF-κB activity in hemopoietic progenitor cells. J. Immunol. 167, 4458-4467 (2001).
99. Rodig, S. J. et al. TRAF1 expression and c-Rel activation are useful adjuncts in distinguishing classical Hodgkin lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. Am. J. Surg. Pathol. 29, 196-203 (2005).
100. Dutton, A., Reynolds, G. M., Dawson, C. W., Young, L. S. & Murray, P. G. Constitutive activation of phosphatidyl-inositide 3 kinase contributes to the survival of Hodgkin's lymphoma cells through a mechanism involving Akt kinase and mTOR. J. Pathol. 205, 498-506 (2005).
101. Georgakis, G. V. et al. Inhibition of the phosphatidylinositol-3 kinase/Akt promotes G1 cell cycle arrest and apoptosis in Hodgkin lymphoma. Br. J. Haematol. 132, 503-511 (2006).
102. Mathas, S. et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J. 21, 4104-4113 (2002).
103. Nagel, S. et al. Comprehensive analysis of homeobox genes in Hodgkin lymphoma cell lines identifies dysregulated expression of HOXB9 mediated via ERK5 signaling and BMI1. Blood 109, 3015-3023 (2007).
104. Renné, C., Willenbrock, K., Küppers, R., Hansmann, M.-L. & Bräuninger, A. Autocrine and paracrine activated receptor tyrosine kinases in classical Hodgkin lymphoma. Blood 105, 4051-4059 (2005).
105. Zheng, B. et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. Blood 102, 1019-1027 (2003).
106. Juszczynski, P. et al. The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc. Natl Acad. Sci. USA 104, 13134-13139 (2007).
107. Watanabe, M. et al. AP-1 mediated relief of repressive activity of the CD30 promoter microsatellite in Hodgkin and Reed-Sternberg cells. Am. J. Pathol. 163, 633-641 (2003).
108. Renné, C. et al. High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia 21, 780-787 (2007).
109. Schmitz, R., Stanelle, J., Hansmann, M.-L. & Küppers, R. Pathogenesis of classical and lymphocytepredominant Hodgkin lymphoma. Annu. Rev. Pathol. (in the press).
110. Anagnostopoulos, I. et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 96, 1889-1899 (2000).
111. Chang, K. C., Khen, N. T., Jones, D. & Su, I. J. Epstein-Barr virus is associated with all histological subtypes of Hodgkin lymphoma in Vietnamese children with special emphasis on the entity of lymphocyte predominance subtype. Hum. Pathol. 36, 747-755 (2005).
112. Dolcetti, R., Boiocchi, M., Gloghini, A. & Carbone, A. Pathogenetic and histogenetic features of HIV-associated Hodgkin's disease. Eur. J. Cancer 37, 1276-1287 (2001).
113. Kutok, J. L. & Wang, F. Spectrum of Epstein-Barr virus-associated diseases. Annu. Rev. Pathol. 1, 375-404 (2006).
114. Baumforth, K. R. et al. Expression of the Epstein-Barr virus-encoded Epstein-Barr virus nuclear antigen 1 in Hodgkin's lymphoma cells mediates up-regulation of CCL20 and the migration of regulatory T cells. Am. J. Pathol. 173, 195-204 (2008).
115. Flavell, J. R. et al. Down-regulation of the TGF-β target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells. Blood 111, 292-301 (2008).
116. Kulwichit, W. et al. Expression of the Epstein-Barr virus latent membrane protein 1 induces B cell lymphoma in transgenic mice. Proc. Natl Acad. Sci. USA 95, 11963-11968 (1998).
117. Kilger, E., Kieser, A., Baumann, M. & Hammerschmidt, W. Epstein-Barr virus-mediated B-cell proliferation is dependent upon latent membrane protein 1, which simulates an activated CD40 receptor. EMBO J. 17, 1700-1709 (1998).
118. Young, L. S. & Murray, P. G. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene 22, 5108-5121 (2003).
119. Alber, G. et al. Molecular mimicry of the antigen receptor signalling motif by transmembrane proteins of the Epstein-Barr virus and the bovine leukemia virus. Curr. Biol. 3, 333-339 (1993).
120. Caldwell, R. G., Wilson, J. B., Anderson, S. J. & Longnecker, R. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals. Immunity 9, 405-411 (1998).
121. Liu, Y. J. et al. Mechanism of antigen-driven selection in germinal centres. Nature 342, 929-931 (1989).
122. Portis, T., Dyck, P. & Longnecker, R. Epstein-Barr Virus (EBV) LMP2A induces alterations in gene transcription similar to those observed in Reed-Sternberg cells of Hodgkin lymphoma. Blood 102, 4166-4178 (2003).
123. Vockerodt, M. et al. The Epstein-Barr virus oncoprotein, latent membrane protein-1, reprograms germinal centre B cells towards a Hodgkin's Reed-Sternberg-like phenotype. J. Pathol. 216, 83-92 (2008).
124. Renné, C. et al. The aberrant coexpression of several receptor tyrosine kinases is largely restricted to EBV-negative cases of classical Hodgkin's lymphoma. Int. J. Cancer 120, 2504-2509 (2007).
125. Bechtel, D., Kurth, J., Unkel, C. & Küppers, R. Transformation of BCR-deficient germinal-center B cells by EBV supports a major role of the virus in the pathogenesis of Hodgkin and posttransplantation lymphomas. Blood 106, 4345-4350 (2005).
126. Mancao, C., Altmann, M., Jungnickel, B. & Hammerschmidt, W. Rescue of "crippled" germinal center B cells from apoptosis by Epstein-Barr virus. Blood 106, 4339-4344 (2005).
127. Chaganti, S. et al. Epstein-Barr virus infection in vitro can resue germinal centre B cells with inactivated immunoglobulin genes. Blood 106, 4249-4252 (2005).
128. Mancao, C. & Hammerschmidt, W. Epstein-Barr virus latent membrane protein 2A is a B-cell receptor mimic and essential for B-cell survival. Blood 110, 3715-3721 (2007).
129. Bräuninger, A. et al. Molecular biology of Hodgkin and Reed/Sternberg cells in Hodgkin's lymphoma. Int. J. Cancer 118, 1853-1861 (2006).
130. Ward, R. J. & Dirks, P. B. Cancer stem cells: at the headwaters of tumor development. Annu. Rev. Pathol. 2, 175-189 (2007).
131. Drexler, H. G., Gignac, S. M., Hoffbrand, A. V. & Minowada, J. Formation of multinucleated cells in a Hodgkin's-disease-derived cell line. Int. J. Cancer 43, 1083-1090 (1989).
132. Newcom, S. R., Kadin, M. E. & Phillips, C. L-428 Reed-Sternberg cells and mononuclear Hodgkin's cells arise from a single cloned mononuclear cell. Int. J. Cell Cloning 6, 417-431 (1988).
133. Jansen, M. P. et al. Morphologically normal, CD30-negative B-lymphocytes with chromosome aberrations in classical Hodgkin's disease: the progenitor cell of the malignant clone? J. Pathol. 189, 527-532 (1999).
134. Barrios, L. et al. Chromosome abnormalities in peripheral blood lymphocytes from untreated Hodgkin's patients. A possible evidence for chromosome instability. Hum. Genet. 78, 320-324 (1988).
135. M'Kacher, R. et al. Baseline and treatment-induced chromosomal abnormalities in peripheral blood lymphocytes of Hodgkin's lymphoma patients. Int. J. Radiat. Oncol. Biol. Phys. 57, 321-326 (2003).
136. Spieker, T. et al. Molecular single-cell analysis of the clonal relationship of small Epstein-Barr virus-infected cells and Epstein-Barr virus-harboring Hodgkin and Reed/Sternberg cells in Hodgkin disease. Blood 96, 3133-3138 (2000).
137. Skinnider, B. F. & Mak, T. W. The role of cytokines in classical Hodgkin lymphoma. Blood 99, 4283-4297 (2002).
138. Aldinucci, D. et al. Expression of CCR5 receptors on Reed-Sternberg cells and Hodgkin lymphoma cell lines: involvement of CCL5/Rantes in tumor cell growth and microenvironmental interactions. Int. J. Cancer 122, 769-776 (2008).
139. Fischer, M. et al. Expression of CCL5/RANTES by Hodgkin and Reed-Sternberg cells and its possible role in the recruitment of mast cells into lymphomatous tissue. Int. J. Cancer 107, 197-201 (2003).
140. Kapp, U. et al. Disseminated growth of Hodgkin's-derived cell lines L540 and L540cy in immune-deficient SCID mice. Ann. Oncol. 5 (Suppl. 1),121-126 (1994).
141. Biggar, R. J. et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 108, 3786-3791 (2006).
142. Aldinucci, D. & Gattei, V. Interleukin-3 receptors in Hodgkin's disease. Am. J. Pathol. 162, 356-357 (2003).
143. Aldinucci, D. et al. Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells. Am. J. Pathol. 160, 585-596 (2002).
144. Aldinucci, D., Lorenzon, D., Olivo, K., Rapana, B. & Gattei, V. Interactions between tissue fibroblasts in lymph nodes and Hodgkin/Reed- Sternberg cells. Leuk. Lymphoma 45, 1731-1739 (2004).
145. Jundt, F. et al. Hodgkin/Reed-Sternberg cells induce fibroblasts to secrete eotaxin, a potent chemoattractant for T cells and eosinophils. Blood 94, 2065-2071 (1999).
146. + T-cell function in Hodgkin lymphoma patients. Blood 108, 2280-2289 (2006). References 106 and 146 showed that secretion of galectin 1 by HRS cells is involved in the suppression of cytotoxic T-cell responses against the HRS cells.
147. Marshall, N. A. et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 103, 1755-1762 (2004). This article established that regulatory T cells are frequently found in the Hodgkin's lymphoma microenvironment.
148. + naive T cells. J. Leukoc. Biol. 82, 576-584 (2007).
149. Alvaro, T. et al. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin. Cancer Res. 11, 1467-1473 (2005).
150. + cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am. J. Clin. Pathol. 128, 958-965 (2007).
151. Tan, T. T. & Coussens, L. M. Humoral immunity, inflammation and cancer. Curr. Opin. Immunol. 19, 209-216 (2007).
152. Gandhi, M. K. et al. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 110, 1326-1329 (2007).
153. Newcom, S. R. & Gu, L. Transforming growth factor β 1 messenger RNA in Reed-Sternberg cells in nodular sclerosing Hodgkin's disease. J. Clin. Pathol. 48, 160-163 (1995).
154. + T cell activation by inhibition of lck: implications in Hodgkin's lymphoma. Cancer Res. 66, 1114-1122 (2006).
155. + T cells in Hodgkin lymphoma. Blood 110, 3226-3233 (2007).
156. Yamamoto, R. et al. PD-1-PD-1 ligand interaction contributes to immunosuppressive microenvironment of Hodgkin lymphoma. Blood 111, 3220-3224 (2008).
157. Hjalgrim, H. et al. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res. 67, 2382-2388 (2007).
158. Kurth, J., Hansmann, M.-L., Rajewsky, K. & Küppers, R. Epstein-Barr virus-infected B cells expanding in germinal centers of infectious mononucleosis patients do not participate in the germinal center reaction. Proc. Natl Acad. Sci. USA 100, 4730-4735 (2003).
159. Kurth, J. et al. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity 13, 485-495 (2000).
160. Buglio, D. et al. Vorinostat inhibits STAT6-mediated TH2 cytokine and TARC production and induces cell death in Hodgkin lymphoma cell lines. Blood 112, 1424-1433 (2008).
161. Hartmann, S. et al. Detection of genomic imbalances in microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma by array-based comparative genomic hybridization. Haematologica 93, 1318-1326 (2008).
162. Gutensohn, N. & Cole, P. Epidemiology of Hodgkin's disease. Semin. Oncol. 7, 92-102 (1980).
163. Kluiver, J. et al. BIC and miR-155 are highly expressed in Hodgkin, primary mediastinal and diffuse large B cell lymphomas. J. Pathol. 207, 243-249 (2005).
164. Nie, K. et al. MicroRNA-mediated down-regulation of PRDM1/Blimp-1 in Hodgkin/Reed-Sternberg cells: a potential pathogenetic lesion in Hodgkin lymphomas. Am. J. Pathol. 173, 242-252 (2008).